High miR-34a expression improves response to doxorubicin in diffuse large B-cell lymphoma

Sara Correia Marques(Chr. Hansen (Denmark)), Karen Dybkær(Aalborg University Hospital), Alexander Schmitz(Chr. Hansen (Denmark)), Maria Bach Laursen(Chr. Hansen (Denmark)), Hans Erik Johnsen(Herlev Hospital), Julie Støve Bødker(Chr. Hansen (Denmark)), Steffen Falgreen(Chr. Hansen (Denmark)), Benyamin Ranjbar(Aarhus University), Martin Bøgsted(Chr. Hansen (Denmark)), Anders Ellern Bilgrau(Chr. Hansen (Denmark)), Jacob Giehm Mikkelsen(Aarhus University), Marianne Schmidt Ettrup(Aalborg University Hospital), Laura Krogh Jørgensen(Aalborg University Hospital), Maria Nascimento Primo(Aarhus University)

Experimental Hematology

February 19, 2016

10.1016/j.exphem.2015.12.007

Cited by 68

Related Papers

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

|Blood|2013|683

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

|Blood|2012|396

Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma

|Blood|2009|390

Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

|Leukemia|2012|362

IFI16 senses DNA forms of the lentiviral replication cycle and controls HIV-1 replication

|Proceedings of the National Academy of Sciences|2013|342